title: Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.
abstract: BACKGROUND
  Secondary central nervous system (CNS) involvement by aggressive lymphoma is a well-known and dreadful clinical complication. The incidence and risk factors for CNS manifestation were studied in a large cohort of elderly (>60 years) patients with aggressive lymphoma.
  
  
  METHODS
  In all, 444 previously untreated patients were randomized to receive 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) (doxorubicin substituted by mitoxantrone) chemotherapy with or without filgrastim. Prophylactic intrathecal methotrexate was given to patients with lymphoma involvement of bone marrow, testis and CNS near sites.
  
  
  RESULTS
  In all 29 of 444 (6.5%) developed CNS disease after a median observation time of 115 months. CNS was the only site of progression/relapse in 13 patients while part of a systemic disease manifestation in 16 patients. In univariate risk factor analysis, CNS occurrence was associated with extranodal involvement of testis (P = 0.002), advanced clinical stage (P = 0.005) and increased age-adjusted International Prognostic Index score (aaIPI; P = 0.035). In multivariate analysis, initial involvement of testis remained significant and clinical stage was of borderline significance. The median survival time was 2 months after presentation of CNS disease.
  
  
  CONCLUSIONS
  A significant proportion of elderly patients with advanced aggressive lymphoma will develop CNS disease. CNS occurrence is related to testis involvement, advanced clinical stage and high aaIPI and the prognosis is dismal.
authors.affiliation: Department of Medicine, Karolinska University Hospital, Stockholm, Sweden. magnus.bjorkholm@karolinska.se
authors.forename: M
authors.initials: M
authors.lastname: Björkholm
authors.forename: H
authors.initials: H
authors.lastname: Hagberg
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.forename: S
authors.initials: S
authors.lastname: Kvaloy
authors.forename: L
authors.initials: L
authors.lastname: Teerenhovi
authors.forename: H
authors.initials: H
authors.lastname: Anderson
authors.forename: E
authors.initials: E
authors.lastname: Cavallin-Ståhl
authors.forename: J
authors.initials: J
authors.lastname: Myhre
authors.forename: H
authors.initials: H
authors.lastname: Pertovaara
authors.forename: A
authors.initials: A
authors.lastname: Ost
authors.forename: B
authors.initials: B
authors.lastname: Nilsson
authors.forename: E
authors.initials: E
authors.lastname: Osby
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000453:epidemiology*; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone